News
09-26-2011, 04:50 AM
Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.
More... (http://www.news-medical.net/news/20110926/Genentech-announces-results-of-trastuzumab-emtansine-Phase-II-study-on-HER2-positive-mBC.aspx)
More... (http://www.news-medical.net/news/20110926/Genentech-announces-results-of-trastuzumab-emtansine-Phase-II-study-on-HER2-positive-mBC.aspx)